8th Annual Evercore HealthCONx Conference - December 2-4, 2025
What We Do
We are pioneering safe innovative and novel therapies for patients with fibrotic, autoimmune, and CNS diseases. We focus to alleviate disease while restoring homeostasis through multiple concerted molecular pathways.
Our Science20+
scientists and researchers
8
drug candidates in development
20+
patents filed
For Patients
Your health is our mission. With decades of expertise behind us, we’re at the forefront of developing novel therapies that make a real difference. Our team’s deep rooted knowledge fuels our commitment to pioneering research and bringing safe, effective treatments to you as swiftly as possible. We’re dedicated to transparency and results, ensuring every breakthrough is a beacon of hope for your healthier tomorrow.
For PatientsOur Partnerships
In a strategic alliance, Graviton has joined forces with Ovid Therapeutics to accelerate the development of novel ROCK2 inhibitors, targeting the treatment of Cerebral Cavernous Malformations (CCMs) and orphan CNS indications. We are charged with advancing these promising candidates through Phase 2 clinical trials. Upon completion, Ovid will spearhead the commercialization efforts, delivering this drug to those affected by CCMs and other orphan CNS diseases.
Our Website
Graviton has a long-term partnership with the Chinese pharmaceutical company Sino Biopharmaceutical. Sino Biopharmaceutical is working with Graviton on ROCK2 inhibitors. ROCK2 is involved in several diseases including fibrotic, autoimmune and CNS diseases. The company’s plan is to move forward in clinical programs with further investigation in 2024.
Visit Website
Sanofi has made a pivotal equity investment in Graviton Bioscience, forging a dynamic partnership aimed at propelling our innovative selective ROCK2 inhibitors to new heights. This investment is designed to be a long-term engagement, exploring multiple therapeutic areas, particularly within immunology and metabolic syndromes. Together, we are dedicated to enhancing treatment options and improving patient outcomes across the globe.